Quinine‑Induced Hemolysis (G6PD Deficiency)

Overview

Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells, affecting an estimated 400 million people worldwide (WHO, 2021). The condition is inherited in an X‑linked recessive pattern, so it is most prevalent in males, although females can be symptomatic when they are homozygous or heterozygous with skewed X‑inactivation.

Quinine, a naturally occurring alkaloid historically used to treat malaria and to relieve nighttime leg cramps, can trigger oxidative stress in individuals with G6PD deficiency. When the antioxidant capacity of red blood cells is overwhelmed, the cells rupture—a process called **hemolysis**. This guide explains the signs, diagnosis, treatment, and daily management of quinine‑induced hemolysis in people with G6PD deficiency.

Symptoms

Symptoms typically appear within hours to a few days after exposure to quinine. The intensity varies with the dose, the underlying G6PD variant, and the individual’s overall health.

• Fatigue / Weakness – Result of anemia from destroyed red blood cells.
• Pallor – Noticeable paleness of the skin, lips, and nail beds.
• Jaundice – Yellowing of the eyes and skin due to increased bilirubin.
• Dark urine – Hemoglobin released from lysed cells gives urine a tea‑colored appearance.
• Back or abdominal pain – Often linked to kidney involvement.
• Rapid heart rate (tachycardia) – The body compensates for reduced oxygen‑carrying capacity.
• Shortness of breath – Particularly on exertion.
• Headache or dizziness – Due to decreased cerebral oxygen delivery.
• Fever – May accompany hemolysis or indicate an underlying infection.
• Splenomegaly – An enlarged spleen can develop with repeated hemolytic episodes.
• Hemoglobinuria – Presence of free hemoglobin in urine; can be confirmed with a dipstick test.

Causes and Risk Factors

Primary cause

Quinine acts as an oxidative agent. In G6PD‑deficient erythrocytes, the pentose‑phosphate pathway cannot generate sufficient NADPH, a molecule needed to keep glutathione in its reduced, protective form. Without adequate reduced glutathione, free radicals damage the cell membrane, leading to hemolysis.

Risk factors

• Genetic deficiency – Presence of a pathogenic G6PD variant (e.g., Mediterranean, Mahidol, African A‑, or Canton). The severity differs per variant.
• Male sex – Males have only one X chromosome, so a single defective allele causes full expression.
• Ethnic background – Higher prevalence in people of African, Mediterranean, Middle Eastern, and Southeast Asian ancestry (Mayo Clinic, 2023).
• High‑dose or repeated quinine exposure – Including over‑the‑counter night‑cramp tablets or malaria prophylaxis.
• Co‑existing stresses – Infections, other oxidative drugs (e.g., sulfonamides, primaquine, dapsone), or acute illnesses can lower the threshold for hemolysis.

Diagnosis

Identifying quinine‑induced hemolysis requires a combination of clinical assessment and laboratory testing.

1. Clinical history

• Recent ingestion of quinine (dose, timing, formulation).
• Family or personal history of G6PD deficiency.
• Symptoms consistent with hemolysis.

2. Laboratory tests

• Complete blood count (CBC) – Shows a sudden drop in hemoglobin/hematocrit and may reveal reticulocytosis (elevated young red cells).
• Peripheral blood smear – Shows bite cells, Heinz bodies (after special staining), or fragmented red cells.
• Lactate dehydrogenase (LDH) – Elevated due to cell breakdown.
• Indirect bilirubin – Increases as the liver processes hemoglobin.
• Haptoglobin – Decreases because it binds free hemoglobin.
• Urinalysis – Positive for blood on dipstick but no red cells on microscopy indicates hemoglobinuria.
• G6PD enzyme assay – Quantitative spectrophotometric test; must be performed >7 days after an acute hemolytic episode to avoid false‑normal results (NIH, 2022).
• Genetic testing (optional) – DNA analysis can identify the specific G6PD variant, useful for counseling.

3. Differential diagnosis

Other causes of acute hemolysis (e.g., autoimmune hemolytic anemia, sickle cell crisis, drug‑induced hemolysis from other agents) must be ruled out.

Treatment Options

Management focuses on stopping the oxidative trigger, supporting the patient’s oxygen‑carrying capacity, and preventing complications.

Immediate measures

1. Discontinue quinine – Remove the offending agent as soon as hemolysis is suspected.
2. Hydration – Intravenous isotonic saline (e.g., 0.9 % NaCl) maintains renal perfusion and helps flush hemoglobin from the kidneys.
3. Transfusion – Packed red blood cells are indicated for symptomatic anemia (Hb < 7 g/dL in adults or < 8 g/dL with cardiovascular disease). Use washed or antigen‑matched units if the patient has alloantibodies.

Pharmacologic therapy

• Corticosteroids – Not routinely recommended because hemolysis is non‑immune; may be considered if an autoimmune component is suspected.
• Folinic acid (Leucovorin) – Sometimes used empirically to aid red‑cell recovery, though evidence is limited.
• Erythropoiesis‑stimulating agents – Rarely required; reserved for chronic cases with prolonged anemia.

Supportive care

• Monitoring of renal function (creatinine, urine output).
• Fever control with acetaminophen (avoid NSAIDs if renal function is compromised).
• Vitamin C in low doses (antioxidant) – Discuss with a clinician; high doses can increase oxalate load.

Follow‑up

After stabilization, repeat CBC and G6PD assay (at least 2–3 weeks later) to confirm deficiency. Counseling about avoidance of quinine and other oxidant drugs is essential.

Living with Quinine‑Induced Hemolysis (G6PD Deficiency)

Daily management tips

• Know your diagnosis – Carry a medical alert card or wearable ID stating “G6PD deficiency – avoid quinine, sulfonamides, dapsone, and certain antimalarials.”
• Medication review – Before starting any new prescription or OTC product, ask your pharmacist or physician about G6PD safety.
• Nutrition – A balanced diet rich in folate (leafy greens, legumes) supports red‑cell production. Limit foods that can increase oxidative stress (e.g., fava beans—classic trigger for “favism”).
• Hydration – Aim for at least 2 L of water daily, more if exercising or in hot climates.
• Regular health checks – Annual CBC and kidney function tests, especially if you have a history of severe hemolysis.
• Travel planning – If traveling to malaria‑endemic areas, discuss alternative prophylaxis (e.g., atovaquone/proguanil) with your clinician.
• Family screening – Because G6PD deficiency is hereditary, consider testing relatives, especially male siblings and future children.

Prevention

• Avoid quinine‑containing products – This includes over‑the‑counter nighttime leg‑cramp tablets, tonic water (contains quinine), and some herbal remedies.
• Screen before exposure – Many malaria‑endemic regions now recommend G6PD testing prior to prescribing primaquine or tafenoquine; similar diligence is warranted for quinine.
• Educate caregivers and pharmacists – Ensure they are aware of the interaction between quinine and G6PD deficiency.
• Stay up‑to‑date on drug lists – Reputable sources (e.g., CDC, Mayo Clinic) maintain searchable tables of G6PD‑unsafe medications.
• Vaccinations – Prevent infections that could precipitate hemolysis (e.g., influenza, pneumococcal vaccine).

Complications

If hemolysis is not promptly recognized or treated, several serious outcomes may develop:

• Acute kidney injury (AKI) – Free hemoglobin can precipitate in renal tubules, leading to obstructive nephropathy.
• Severe anemia – May cause cardiac strain, heart failure, or syncope.
• Rhabdomyolysis – Occasionally co‑occurs, worsening kidney injury.
• Hyperbilirubinemia & Kernicterus (in infants) – High bilirubin can cross the blood‑brain barrier.
• Chronic hemolysis – Repeated episodes can cause splenomegaly, gallstones (pigment stones), and iron overload.
• Increased mortality – Particularly when AKI or severe anemia is left untreated (Cleveland Clinic, 2022).

When to Seek Emergency Care

References

1. World Health Organization. G6PD deficiency: a focus for public health interventions. WHO Press, 2021.
2. Mayo Clinic. “G6PD deficiency.” Updated 2023. https://www.mayoclinic.org
3. National Institutes of Health. “Glucose‑6‑phosphate dehydrogenase deficiency.” Genetics Home Reference, 2022.
4. Cleveland Clinic. “Hemolytic anemia.” Patient Health Library, 2022.
5. Centers for Disease Control and Prevention. “Drug safety in G6PD deficiency.” 2023. https://www.cdc.gov
6. Quinine and oxidative hemolysis: a review. Journal of Hematology. 2021;12(4):215‑224.